A clinical trial out of the University of California San Diego School of Medicine found that neural stem cell transplantation had shown long-term safety and feasibility for treating chronic spinal cord injuries.
Biologics
Theradaptive earned the FDA's investigational device exemption approval to broaden its clinical research for the OsteoAdapt SP implant, the company said Dec. 10.
Three-year data for the Discseel spine procedure found it was effective and could replace most spine surgeries, Discseel Technologies said Dec. 4.
Bioretec signed a distribution agreement to accelerate commercialization of the RemeOs trauma screw system in the U.S., according to a Nov. 22 news release.
From company acquisitions to FDA nods, here are six key updates in orthobiologics since Oct. 4.
Advertisement
Acuitive Technologies earned FDA clearance for the Citrepore bioactive bone filler, the company said Nov. 12.
Biologics company Theradaptive's lead therapeutic, OsteoAdapt SP, has been featured in a preclinical spinal fusion study published in Spine, a prominent, peer-reviewed publication for spinal surgeons.
Spine biologics holds incredible potential if it can overcome obstacles related to disc anatomy, Ezriel Kornel, MD, said.
CytexOrtho has earned FDA approval to begin a clinical trial evaluating the safety and efficacy of its absorbable hip implant in human patients, according to an Oct. 29 report from Mass Device.
Washington, D.C.-based Regenerative Orthopedics & Sports Medicine has partnered with the Orthobiologics Research Initiative to support nonsurgical orthopedic research aimed at treating partial-thickness rotator cuff tears using cutting-edge orthobiologic procedures.